Inhibikase Therapeutics (IKT) Asset Utilization Ratio (2021 - 2023)
Historic Asset Utilization Ratio for Inhibikase Therapeutics (IKT) over the last 4 years, with Q3 2024 value amounting to 0.0.
- Inhibikase Therapeutics' Asset Utilization Ratio fell 9999.91% to 0.0 in Q3 2024 from the same period last year, while for Sep 2024 it was 0.0, marking a year-over-year decrease of 9999.91%. This contributed to the annual value of 0.01 for FY2023, which is 26064.89% up from last year.
- Inhibikase Therapeutics' Asset Utilization Ratio amounted to 0.0 in Q3 2024, which was down 9999.91% from 0.01 recorded in Q2 2024.
- In the past 5 years, Inhibikase Therapeutics' Asset Utilization Ratio registered a high of 0.14 during Q1 2021, and its lowest value of 0.0 during Q3 2024.
- In the last 4 years, Inhibikase Therapeutics' Asset Utilization Ratio had a median value of 0.02 in 2024 and averaged 0.03.
- Its Asset Utilization Ratio has fluctuated over the past 5 years, first soared by 71541.88% in 2023, then crashed by 9999.91% in 2024.
- Quarter analysis of 4 years shows Inhibikase Therapeutics' Asset Utilization Ratio stood at 0.07 in 2021, then plummeted by 93.43% to 0.0 in 2022, then surged by 248.72% to 0.02 in 2023, then tumbled by 100.0% to 0.0 in 2024.
- Its Asset Utilization Ratio was 0.0 in Q3 2024, compared to 0.01 in Q2 2024 and 0.02 in Q1 2024.